Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- Proactive palliative care increases in prominence for advanced HF management
-
- FDA approves PFO occlusion device for reduction of recurrent stroke risk
- Self-expanding TAVR system approved in larger size
- ATACAS: Outcomes mixed for tranexamic acid vs. placebo in patients undergoing coronary artery surgery
- Caffeine does not increase short-term risk for arrhythmias in patients with HF
- Greater intensity of statin therapy confers increased mortality benefit
- Long-term study highlights link between sodium intake, mortality
- Machine-learning algorithms fail to improve prediction of 30-day HF readmissions
- Sex-specific risk scores predict mortality in patients undergoing exercise testing
-
- Spironolactone may benefit exercise capacity in certain patients with HFpEF
- EUCLID: Ticagrelor not superior to clopidogrel for CV event reduction in patients with PAD
- GARY: 1-year mortality higher with TAVR vs. surgery in real-world population
- GLAGOV: Evolocumab added to statin therapy induces greater plaque regression
- New guidelines emphasize medical therapy, structured exercise for patients with PAD
- New LVAD associated with improved 6-month outcomes in patients with advanced HF
- NOBLE: CABG shows better clinical outcomes for treatment of left main CAD vs. PCI
- PIONEER AF-PCI: Bleeding lower with rivaroxaban regimens in patients with AF needing PCI
-
- PRECISION: CV risk with celecoxib not greater than with ibuprofen, naproxen
- ‘Real-world’ data show promise for left atrial appendage closure device
- TRUE-AHF: Ularitide improves congestion, does not reduce CV death in patients with acute HF
- Bariatric surgery ‘powerful’ tool for understanding biology of obesity
- For SGLT2 inhibitors, big benefits come with some trade-offs
- Lower BP confers better outcomes, even in patients with diabetes
- Opportunities, challenges shape the landscape of lipid management
- SPRINT results reinforce connection between hypertension, HF
-
- Triglyceride-rich lipoproteins play causal role in CV risk
- Trial Scorecard: BIO-RESORT (TWENTE III)
- Trial Scorecard: CORONARY
- Trial Scorecard: EUCLID
- Trial Scorecard: EXCEL
- Trial Scorecard: GLAGOV
- Trial Scorecard: PRECISION
- Trial Scorecard: STRUCTURE
-
- Trial Scorecard: TRUE-AHF